federal_register: E5-8120
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| E5-8120 | Prospective Grant of Exclusive License: Implants for Sustained Ocular Therapeutic Agent Delivery | Notice | This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the invention embodied in E- 241-1999/0, "Ocular Therapeutic Agent Delivery Devices And Methods For Making And Using Such Devices;" U.S. Patent 6,713,081 issued March 30, 2004 and expires March 15, 2021; U.S. Patent Application 10/471,468 filed September 12, 2004; and European Patent Application 02723446.7 filed March 14, 2002; to Lux Biosciences, a Delaware corporation having a principle place of business in Jersey City, New Jersey. The United States of America is the assignee of the patent rights of the above inventions. The contemplated exclusive license may be granted in the field of ocular cyclosporine A delivery for the treatment of graft-versus-host- disease-associated dry eye and Sj[ouml]gren's Syndrome. | 2005-12-30 | 2005 | 12 | https://www.federalregister.gov/documents/2005/12/30/E5-8120/prospective-grant-of-exclusive-license-implants-for-sustained-ocular-therapeutic-agent-delivery | https://www.govinfo.gov/content/pkg/FR-2005-12-30/pdf/E5-8120.pdf | Health and Human Services Department; National Institutes of Health | 221,353 | This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the... |